Swiss DolorClast is EMS Swiss' entry in the shockwave category, built on Radial Pressure Wave (RPW) Shockwave. The platform treats plantar fasciitis, lateral epicondylitis, calcific tendinitis, patellar tendinopathy, with 5-15 minutes per area and a recommended course of 3-5 sessions. FDA cleared in 2013, it lists in the $40,000-$75,000 range for new units and $18,000-$38,000 on the secondary market.
75+ peer-reviewed studies across plantar fasciitis, calcific shoulder tendinitis, lateral epicondylitis, and patellar tendinopathy. EMS Swiss has refined the Swiss DolorClast applicator system over 20+ years, and the device appears in more clinical research protocols than any other radial shockwave platform. Three transmitter sizes (6mm, 15mm, 36mm) cover everything from trigger points to large muscle groups without hardware swaps. The mechanism is what separates Swiss DolorClast from competitors in the same category. Where it fits in your practice depends on patient demographics, treatment volume, and whether you need a flagship platform or a value-tier alternative.
Swiss DolorClast is manufactured by EMS Swiss (Nyon, Switzerland, founded 1981). The device benefits from EMS Swiss' long manufacturer history and presence across 100+ countries. Service support, training availability, and parts access vary by region. Practices considering this device should validate dealer presence and technical support coverage in their area before signing a contract.
75+ peer-reviewed studies: deepest evidence base in radial shockwave
Three transmitter sizes handle trigger points to large muscle groups
Swiss-manufactured build quality with longer service intervals than competitors
Used in academic sports medicine and research protocols globally
Strong international parts availability through EMS network
Cons
Radial pressure wave only: no focused shockwave for deep calcifications
EMS US dealer coverage is limited outside major metro markets
List price ($40K-$75K) runs higher than Chattanooga RPW for equivalent radial output
Parts turnaround times in the US run longer than Chattanooga or Storz
Brand recognition in the US trails Storz DUOLITH among combined-platform buyers
Clinical Evidence
75+ published peer-reviewed studies across plantar fasciitis, calcific shoulder tendinitis, lateral epicondylitis, and Achilles tendinopathy. Multiple randomized controlled trials with blinded evaluators. Among the most-cited shockwave platforms in PubMed-indexed research. Study funding is mixed between independent and EMS-sponsored, which is typical for the category. The published evidence base for Swiss DolorClast reflects how long the platform has been in market and how much the manufacturer has invested in clinical research. Devices with FDA clearance dates before 2018 typically have stronger peer-reviewed datasets than newer entrants. For physicians evaluating this device, the questions worth asking are whether the studies used blinded evaluators, what the sample sizes were, and whether the research was independent or manufacturer-funded.
Compare Swiss DolorClast's evidence base against the category benchmark. In Swiss DolorClast's category, the strongest evidence typically comes from devices that have been on the market for at least five years and have multiple randomized controlled trials with independent funding. Marketing claims from any manufacturer should be cross-checked against PubMed-indexed publications rather than conference posters or white papers. Conference presentations are not equivalent to peer review.
For practices that require strong clinical evidence (academic dermatology, plastic surgery groups with research interests, multi-physician practices that need to defend purchase decisions internally), the evidence profile should be a top-three decision factor. For high-volume cash-pay practices where patient demand drives device selection, brand recognition often matters more than the underlying evidence base. Both approaches are defensible, but they lead to different device selections.
ROI Analysis
Practice ROI for Swiss DolorClast depends on three variables: capital cost, per-session revenue, and treatment volume. At a new unit price of $40,000-$75,000, financed over five years at typical equipment rates, the monthly payment runs roughly 2-2.5% of total cost. Per-session revenue at $100-$350 means the device needs to fill enough treatment slots monthly to cover the payment, consumables ($500-$1,500), maintenance ($2,500-$5,000), and operator labor.
For a practice doing 2-3 treatments per day at the midpoint of the per-session range, Swiss DolorClast typically reaches break-even at 12-18 months for the lower end of the new pricing range, or 18-30 months at the high end. Used and refurbished units in the $18,000-$38,000 range can cut payback periods in half. The biggest practice mistake is over-projecting treatment volume. Physicians who run their numbers on 4-6 daily treatments rarely hit those targets in year one.
The realistic question is not whether Swiss DolorClast can pay back. Most devices in this price range do, eventually. The question is whether your practice can fill the schedule. Practices with existing patient flow in Physical Therapy, Orthopedics have the easiest path. Practices building demand from scratch should plan for 6-12 months of marketing investment before the device pays for itself.
Best For
Academic sports medicine programs, high-volume physical therapy clinics, and research-oriented practices that need to reference peer-reviewed evidence when defending purchase decisions internally. Practices that treat plantar fasciitis and calcific tendinitis at high volume and want the device with the deepest published evidence per indication. The fit is strongest for practices that match the device's positioning on price, clinical evidence requirements, and patient throughput expectations. Practices with mismatched economics often regret these purchases within 18 months.
Beyond practice type, Swiss DolorClast fits best when the patient base aligns with the device's strengths. For shockwave platforms, this usually means matching device capability to patient demographics, skin type range, and willingness to pay per-session pricing. Practices in markets where patients price-shop heavily need to factor that into device selection. Practices in concierge or luxury markets can charge premium pricing that justifies premium platforms.
Buying Guide
New Swiss DolorClast units sell for $40,000-$75,000 from EMS Swiss or authorized dealers. Refurbished and used units sell for $18,000-$38,000 on the secondary market. The decision between new and used comes down to warranty coverage, software version, included applicators, and consumable allowances. New units typically include a 12-24 month warranty, current software, all applicators, and a starter consumable package. Used units usually carry no warranty, may have outdated software, and require separate consumable purchases.
What to negotiate: applicator quantity (always ask for additional applicators thrown in), consumable starter packs, training and certification fees, extended warranty coverage, marketing materials, and clinical training for additional providers. EMS Swiss sales reps typically have 10-15% list price flexibility and far more on bundled deals. End-of-quarter and end-of-year are the strongest negotiation windows. Trade-in programs for older devices can reduce net cost by another 10-20%.
What to watch for: software lock-out fees on used units (some manufacturers disable software on resold devices), per-pulse or per-treatment licensing fees that show up after purchase, consumable price increases over the device life, and service contract terms. Always require a written quote that breaks out hardware, applicators, training, first-year service, and consumables separately. Bundled quotes hide the line items where margins live.
Alternatives and Comparisons
The main alternatives to Swiss DolorClast in this category are listed below. Click into any comparison for a full side-by-side breakdown.
DUOLITH SD1: Sports medicine practices and orthopedic clinics that want the most versatile shockwave platform. Practices that see complex tendinopathies requiring focused th
MASTERPULS MP200: Physical therapy, chiropractic, and sports medicine practices that need radial shockwave at a moderate capital cost. Practices building a dedicated shockwave se
SoftWave OrthoGold 100: Chiropractic, regenerative medicine, and integrative practices that can charge premium cash-pay pricing and want territory scarcity from SoftWave TRT's authoriz
Chattanooga RPW: Physical therapy clinics that want entry-level radial shockwave capability with familiar Chattanooga service and training. Practices adding shockwave to an exis
New Swiss DolorClast units sell for $40,000-$75,000 from EMS Swiss and authorized dealers. Used and refurbished units typically run $18,000-$38,000 on the secondary market depending on age, software version, and included applicators. Per-session pricing for treatments is $100-$350. Annual consumables run $500-$1,500 and annual maintenance averages $2,500-$5,000. Practices financing the device should expect monthly payments around 2-2.5% of the total purchase price over a five-year term.
Is Swiss DolorClast FDA cleared?
Yes. Swiss DolorClast received FDA 510(k) clearance in 2013. The clearance covers the indications listed in the device labeling. Off-label uses are common in clinical practice but should be discussed with patients explicitly. Physicians should verify current clearance status and any updates directly with EMS Swiss or via the FDA 510(k) database before making a purchase decision.
What is the clinical evidence behind Swiss DolorClast?
75+ published peer-reviewed studies across plantar fasciitis, calcific shoulder tendinitis, lateral epicondylitis, and Achilles tendinopathy. Multiple randomized controlled trials with blinded evaluators. Among the most-cited shockwave platforms in PubMed-indexed research. Study funding is mixed between independent and EMS-sponsored, which is typical for the category. When evaluating clinical evidence, look for blinded evaluator studies, independent funding sources, and peer-reviewed publications rather than manufacturer-funded white papers or conference posters. Evidence quality varies widely between devices in the same category, even when the marketing materials look similar.
Which specialties use Swiss DolorClast?
Swiss DolorClast is primarily used by Physical Therapy, Orthopedics, Sports Medicine, Urology, Podiatry. Best fit varies by patient mix and practice economics. Academic sports medicine programs, high-volume physical therapy clinics, and research-oriented practices that need to reference peer-reviewed evidence when defending purchase decisions internally. Practices that treat plantar fasciitis and calcific tendinitis at high volume and want the device with the deepest published evidence per indication.
How long does a Swiss DolorClast treatment session take?
Each Swiss DolorClast treatment session runs 5-15 minutes per area. The recommended protocol is 3-5 sessions. Total chair time including consultation, setup, treatment, and post-treatment care is typically 1.5-2x the listed treatment time. Practices planning daily treatment volume should use the realistic chair-time number, not just the active treatment minutes.
What are the main pros and cons of Swiss DolorClast?
Strengths: 75+ peer-reviewed studies: deepest evidence base in radial shockwave; Three transmitter sizes handle trigger points to large muscle groups; Swiss-manufactured build quality with longer service intervals than competitors. Weaknesses: Radial pressure wave only: no focused shockwave for deep calcifications; EMS US dealer coverage is limited outside major metro markets; List price ($40K-$75K) runs higher than Chattanooga RPW for equivalent radial output. Every device in this category has tradeoffs. The right choice depends on which strengths matter most to your practice and which weaknesses you can tolerate.
What does Swiss DolorClast cost to operate annually?
Annual operating costs for Swiss DolorClast include consumables ($500-$1,500), maintenance and service ($2,500-$5,000), and operator labor. Practices doing high treatment volumes should also budget for additional applicator wear and replacement. Total annual operating cost typically runs 5-15% of the original purchase price, with consumables driving most of the variability between low and high estimates.
Who manufactures Swiss DolorClast and how stable is the company?
Swiss DolorClast is manufactured by EMS Swiss, headquartered in Nyon, Switzerland and founded in 1981. The company is privately held and operates in 100+ countries. Annual revenue is approximately Not disclosed (private). Manufacturer financial stability matters because it affects warranty support, parts availability, and long-term software updates. Physicians making capital purchases should always check the manufacturer's recent financial trajectory before committing.
What does Swiss DolorClast cost in 2026?
As of April 2026, Swiss DolorClast new unit pricing is $40,000-$75,000 from EMS Swiss and authorized dealers. Refurbished and used unit pricing typically runs $18,000-$38,000 on the secondary market. Per-session treatment pricing for patient billing is $100-$350. Pricing has held relatively stable through 2025-2026 across the shockwave category, though specific applicator and consumable pricing varies. Practices should request current quotes directly from EMS Swiss sales for the most accurate 2026 pricing because list price varies meaningfully by region, configuration, and trade-in deals.
How does Swiss DolorClast compare to other shockwave devices in 2026?
In the 2026 shockwave category, Swiss DolorClast competes primarily with the other devices reviewed on DevicePulse: masterpuls, duolith, softwave, chattanooga-rpw. The differentiation comes down to clinical evidence depth, treatment time per session, applicator versatility, and total cost of ownership over a 5-year period. Most practices choose between 2-3 finalists based on specialty mix, patient volume, and existing equipment compatibility. Run a side-by-side total cost of ownership analysis before committing to a capital purchase.
What is the Swiss DolorClast treatment protocol and recommended session count?
The Swiss DolorClast recommended treatment protocol is 3-5 sessions, with each session running 5-15 minutes per area. Total treatment plan duration depends on the indication and patient response. For patient pricing and ROI calculations, multiply per-session pricing ($100-$350) by the recommended session count to get the patient-facing treatment course cost. Practices typically build the treatment plan into a package price rather than billing per session, which improves patient retention through the full protocol.
What's the latest news and updates for Swiss DolorClast in 2026?
As of April 2026, Swiss DolorClast continues commercial availability from EMS Swiss. Recent industry updates relevant to the device include manufacturer financial disclosures, new clinical evidence publications, software updates, and FDA labeling changes. EMS Swiss shares periodic business updates that inform the long-term outlook for Swiss DolorClast support and continued investment. Check the manufacturer's investor relations page or press releases for the most current operational status.
Get Device Pulse every Tuesday
Weekly price tracker, FDA clearances, safety signals, and clinical evidence summaries. The only newsletter built for physicians who buy equipment.